Linjie Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Linjie Zhang has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Jing Sui
Research Institute for Environment and Health, Nanjing University of Information Science and Technology, Nanjing 210044, China
4 shared publications - Hui Xia
Key Laboratory of Environmental Medicine and Engineering of Ministry of Education, Department of Nutrition and Food Hygiene, School of Public Health, Southeast University, Nanjing 210009, China
3 shared publications - Hao Wang
School of Electronic and Information Engineering, Anhui Jianzhu University, Heifei 230601, China
2 shared publications - Qun Zhao
Nanjing University of Information Science and Technology
2 shared publications - Yajie Zhou
Key Laboratory of Environmental Medicine and Engineering of Ministry of Education, Department of Nutrition and Food Hygiene, School of Public Health, Southeast University, Nanjing 210009, China
2 shared publications - Hanlin Yin
Research Institute for Environment and Health, Nanjing University of Information Science and Technology, Nanjing 210044, China
1 shared publication
Latest Publications
- Open Access
- 26 June 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (13) , 5809
Transcriptomic Identification of Diagnostic Biomarkers for Alcohol-Associated Liver Cirrhosis: Integration of Population-Level Epidemiology with Multi-Cohort Transcriptomic Analysis
Alcohol-associated liver cirrhosis (ALC) lacks aetiology-specific molecular diagnostic biomarkers. This study aims to quantify the association between alcohol and cirrhosis risk, and to identify transcriptomic diagnostic biomarkers and candidate therapeutics. Methods: Survey-weighted logistic regression was applied to 17,007 adults from NHANES (2017–2023) to quantify alcohol-cirrhosis associations. ALC transcriptomic data from four GEO datasets were analysed using weighted gene co-expression network analysis (WGCNA) and three parallel machine learning algorithms (LASSO, Random Forest, SVM-RFE). External validation was performed in an independent cohort of 93 samples. Candidate therapeutics were identified via drug signature database querying and validated by molecular docking. Heavy drinking conferred a 5.14-fold increased cirrhosis risk (95% CI: 2.60–10.20, p < 0.001). Transcriptomic analysis revealed global downregulation of long non-coding RNAs (with 91.7% of dysregulated lncRNAs being suppressed). A five-gene diagnostic signature (IL1B, CCL3, LUM, SPP1, ITGA6), specifically developed to distinguish ALC from histologically normal liver tissue, achieved an area under the receiver operating characteristic curve (AUC) of 0.824 in an external validation cohort. Immune infiltration analysis uncovered global contraction of macrophage-associated transcriptomic signatures across M0, M1, and M2 subtypes, inversely correlated with fibrotic hub gene upregulation. Fluvastatin and honokiol were identified as candidate therapeutic agents, with strong binding affinities to IL1B and CCL3, respectively. This study confirms a dose-dependent alcohol-cirrhosis association and establishes a five-gene diagnostic signature (distinguishing ALC from normal liver tissue) alongside candidate therapeutics, warranting prospective clinical validation. The identified tissue-derived signature and therapeutic candidates provide a foundation for future ALC-specific diagnostic and therapeutic strategies; their translation into a non-invasive (e.g., blood-based) assay will require dedicated validation in circulating samples.
- 26 June 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (13) , 5809
Open AccessTranscriptomic Identification of Diagnostic Biomarkers for Alcohol-Associated Liver Cirrhosis: Integration of Population-Level Epidemiology with Multi-Cohort Transcriptomic Analysis
Alcohol-associated liver cirrhosis (ALC) lacks aetiology-specific molecular diagnostic biomarkers. This study aims to quantify the association between alcohol and cirrhosis risk, and to identify transcriptomic diagnostic biomarkers and candidate therapeutics. Methods: Survey-weighted logistic regression was applied to 17,007 adults from NHANES (2017–2023) to quantify alcohol-cirrhosis associations. ALC transcriptomic data from four GEO datasets were analysed using weighted gene co-expression network analysis (WGCNA) and three parallel machine learning algorithms (LASSO, Random Forest, SVM-RFE). External validation was performed in an independent cohort of 93 samples. Candidate therapeutics were identified via drug signature database querying and validated by molecular docking. Heavy drinking conferred a 5.14-fold increased cirrhosis risk (95% CI: 2.60–10.20, p < 0.001). Transcriptomic analysis revealed global downregulation of long non-coding RNAs (with 91.7% of dysregulated lncRNAs being suppressed). A five-gene diagnostic signature (IL1B, CCL3, LUM, SPP1, ITGA6), specifically developed to distinguish ALC from histologically normal liver tissue, achieved an area under the receiver operating characteristic curve (AUC) of 0.824 in an external validation cohort. Immune infiltration analysis uncovered global contraction of macrophage-associated transcriptomic signatures across M0, M1, and M2 subtypes, inversely correlated with fibrotic hub gene upregulation. Fluvastatin and honokiol were identified as candidate therapeutic agents, with strong binding affinities to IL1B and CCL3, respectively. This study confirms a dose-dependent alcohol-cirrhosis association and establishes a five-gene diagnostic signature (distinguishing ALC from normal liver tissue) alongside candidate therapeutics, warranting prospective clinical validation. The identified tissue-derived signature and therapeutic candidates provide a foundation for future ALC-specific diagnostic and therapeutic strategies; their translation into a non-invasive (e.g., blood-based) assay will require dedicated validation in circulating samples.
- 6 May 2026
- Published by Oxford University Press (OUP) in Nutrition Reviews
Alternative Healthy Eating Index and Healthy Eating Index in Relation to Risk of Chronic Liver Diseases: A Meta-Analysis of Observational Studies
Context: Chronic liver disease is a major global health burden, and preventive strategies are crucial, given its insidious progression. Although individual nutrients and foods’ associations with chronic liver disease are studied, dietary patterns’ holistic effects matter more. Objective: This study systematically evaluated the links between 2 healthy dietary indices—the Alternative Healthy Eating Index (AHEI) and the Healthy Eating Index (HEI)—and chronic liver disease, namely, metabolic dysfunction–associated steatotic liver disease, liver fibrosis, cirrhosis, fatty liver, and liver cancer. Data Sources: A systematic literature search was conducted in the PubMed, Web of Science, Cochrane Library, and Embase databases for relevant observational studies published up to February 2025. Data Extraction: Data extraction and quality assessment were performed independently by the authors. A total of 28 articles comprising 50 studies (n = 18 prospective cohort, 25 cross-sectional, and 7 case-control studies) involving 624 914 participants were included. Data Analysis: A random-effects model was used for the meta-analysis. Results showed the AHEI (OR = 0.71; 95% CI, 0.62-0.80) and HEI (OR = 0.68; 95% CI, 0.61-0.77) were significantly negatively associated with chronic liver disease. Subgroup analysis found the AHEI protected against MASLD, liver cancer, and overall chronic liver disease, notably in Asia and North America. The HEI protected against MASLD, fibrosis, liver cancer, and chronic liver disease, with marked effects in North America. This study’s strengths lie in its large sample size, integration of multiple study designs, and rigorous methodological framework, which collectively enhance the generalizability of its results. Conclusions: The findings suggest the AHEI and HEI are associated with a lower risk of chronic liver disease, providing valuable guidance for clinical practice, such as advocating for these dietary patterns among high-risk populations. However, limitations exist, including potential heterogeneity in dietary assessment methods and unaccounted confounders. Future research should address these issues to further optimize chronic liver disease management strategies. Systematic Review Registration: PROSPERO registration no. CRD42025065410
- 6 May 2026
- Published by Oxford University Press (OUP) in Nutrition Reviews
Alternative Healthy Eating Index and Healthy Eating Index in Relation to Risk of Chronic Liver Diseases: A Meta-Analysis of Observational Studies
Context: Chronic liver disease is a major global health burden, and preventive strategies are crucial, given its insidious progression. Although individual nutrients and foods’ associations with chronic liver disease are studied, dietary patterns’ holistic effects matter more. Objective: This study systematically evaluated the links between 2 healthy dietary indices—the Alternative Healthy Eating Index (AHEI) and the Healthy Eating Index (HEI)—and chronic liver disease, namely, metabolic dysfunction–associated steatotic liver disease, liver fibrosis, cirrhosis, fatty liver, and liver cancer. Data Sources: A systematic literature search was conducted in the PubMed, Web of Science, Cochrane Library, and Embase databases for relevant observational studies published up to February 2025. Data Extraction: Data extraction and quality assessment were performed independently by the authors. A total of 28 articles comprising 50 studies (n = 18 prospective cohort, 25 cross-sectional, and 7 case-control studies) involving 624 914 participants were included. Data Analysis: A random-effects model was used for the meta-analysis. Results showed the AHEI (OR = 0.71; 95% CI, 0.62-0.80) and HEI (OR = 0.68; 95% CI, 0.61-0.77) were significantly negatively associated with chronic liver disease. Subgroup analysis found the AHEI protected against MASLD, liver cancer, and overall chronic liver disease, notably in Asia and North America. The HEI protected against MASLD, fibrosis, liver cancer, and chronic liver disease, with marked effects in North America. This study’s strengths lie in its large sample size, integration of multiple study designs, and rigorous methodological framework, which collectively enhance the generalizability of its results. Conclusions: The findings suggest the AHEI and HEI are associated with a lower risk of chronic liver disease, providing valuable guidance for clinical practice, such as advocating for these dietary patterns among high-risk populations. However, limitations exist, including potential heterogeneity in dietary assessment methods and unaccounted confounders. Future research should address these issues to further optimize chronic liver disease management strategies. Systematic Review Registration: PROSPERO registration no. CRD42025065410
- Open Access
The Impact of the Alternate Mediterranean Diet (aMED) on the Prevention of Chronic Liver Disease: A Meta-Analysis of Observational Studies
Conventional research mainly focuses on individual nutrients or specific foods in relation to chronic liver disease, but the cumulative effects of dietary patterns are underexplored. This study aimed to assess current evidence on the alternate Mediterranean Diet (aMED) and chronic liver disease risk via a meta-analysis of observational studies. A systematic search of PubMed, Web of Science, Cochrane, and Embase (up to February 2025) identified studies on aMED and chronic liver disease, using predefined criteria for screening, quality assessment, and data extraction. A total of 20 articles (3 cross-sectional, 15 cohort, and 2 case–control; 1,286,480 participants) were analyzed using a random-effects model. The analysis showed that aMED was significantly negatively correlated with chronic liver disease (OR = 0.65, 95% CI: 0.56–0.75), indicating that adherence reduces risk. Subgroup analysis showed aMED’s protective effects in North America (OR = 0.67, 95% CI: 0.54–0.83) and Europe (OR = 0.54, 95% CI: 0.44–0.66). The results suggest aMED adherence may lower chronic liver disease risk, emphasizing dietary modifications for prevention.
Open AccessThe Impact of the Alternate Mediterranean Diet (aMED) on the Prevention of Chronic Liver Disease: A Meta-Analysis of Observational Studies
Conventional research mainly focuses on individual nutrients or specific foods in relation to chronic liver disease, but the cumulative effects of dietary patterns are underexplored. This study aimed to assess current evidence on the alternate Mediterranean Diet (aMED) and chronic liver disease risk via a meta-analysis of observational studies. A systematic search of PubMed, Web of Science, Cochrane, and Embase (up to February 2025) identified studies on aMED and chronic liver disease, using predefined criteria for screening, quality assessment, and data extraction. A total of 20 articles (3 cross-sectional, 15 cohort, and 2 case–control; 1,286,480 participants) were analyzed using a random-effects model. The analysis showed that aMED was significantly negatively correlated with chronic liver disease (OR = 0.65, 95% CI: 0.56–0.75), indicating that adherence reduces risk. Subgroup analysis showed aMED’s protective effects in North America (OR = 0.67, 95% CI: 0.54–0.83) and Europe (OR = 0.54, 95% CI: 0.44–0.66). The results suggest aMED adherence may lower chronic liver disease risk, emphasizing dietary modifications for prevention.
- Open Access
- 22 January 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (3) , 911
Identification and Evaluation of Hub Long Non-Coding RNAs and mRNAs in PM2.5-Induced Lung Cell Injury
Exposure to air pollution, especially fine particulate matter (PM2.5), is closely linked to various adverse health effects, particularly in the respiratory system. The present study was designed to investigate the lncRNA–mRNA interactions in PM2.5-induced lung cell injury using weighted gene co-expression network analysis (WGCNA). We downloaded the gene expression data of GSE138870 from the Gene Expression Omnibus (GEO) database and screened for differentially expressed lncRNAs and mRNAs. We constructed co-expression modules with WGCNA. Furthermore, functional enrichment analysis was also performed. We also constructed lncRNA–mRNA co-expression networks and lncRNA–mRNA-pathway networks to identify key regulatory relationships. The results revealed several modules significantly correlated with PM2.5-induced lung injury, such as the turquoise and blue modules. Genes within these modules were enriched in pathways related to signal transduction, metabolism, and cancer. Hub lncRNAs in the turquoise module, including LOC100129034 and CROCCP2, were found to be co-expressed with mRNAs involved in apoptosis and proliferation regulation. In the blue module, lnc-CLVS2-2 and GARS1-DT were connected to genes related to cell migration, invasion, and lung injury. These findings contribute novel perspectives to the molecular mechanisms involved in PM2.5-induced lung injury and suggest that WGCNA could be a valuable tool for predicting and understanding this disease process.
- 22 January 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (3) , 911
Open AccessIdentification and Evaluation of Hub Long Non-Coding RNAs and mRNAs in PM2.5-Induced Lung Cell Injury
Exposure to air pollution, especially fine particulate matter (PM2.5), is closely linked to various adverse health effects, particularly in the respiratory system. The present study was designed to investigate the lncRNA–mRNA interactions in PM2.5-induced lung cell injury using weighted gene co-expression network analysis (WGCNA). We downloaded the gene expression data of GSE138870 from the Gene Expression Omnibus (GEO) database and screened for differentially expressed lncRNAs and mRNAs. We constructed co-expression modules with WGCNA. Furthermore, functional enrichment analysis was also performed. We also constructed lncRNA–mRNA co-expression networks and lncRNA–mRNA-pathway networks to identify key regulatory relationships. The results revealed several modules significantly correlated with PM2.5-induced lung injury, such as the turquoise and blue modules. Genes within these modules were enriched in pathways related to signal transduction, metabolism, and cancer. Hub lncRNAs in the turquoise module, including LOC100129034 and CROCCP2, were found to be co-expressed with mRNAs involved in apoptosis and proliferation regulation. In the blue module, lnc-CLVS2-2 and GARS1-DT were connected to genes related to cell migration, invasion, and lung injury. These findings contribute novel perspectives to the molecular mechanisms involved in PM2.5-induced lung injury and suggest that WGCNA could be a valuable tool for predicting and understanding this disease process.